A Phase II Study of AS1411 in Renal Cell Carcinoma

• Status: Unknown status
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Antisoma Research

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed renal cell carcinoma containing predominant clear cell histology

• Failed or intolerant to 1 or more previous lines of treatments (which must include a Tyrosine Kinase Inhibitor)

Exclusion Criteria:

• Collecting duct histology

• A history of bleeding disorders or currently taking oral vitamin K antagonise medication

• Unstable brain metastases

• History of prior or concomitant malignancy (except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancer for which the patient has been disease free for 3 years)